TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of participants with any treatment-emergent serious adverse event (TESAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with any treatment-emergent non-serious adverse event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean total immunoglobulin G (IgG) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Days from extubation to drainage tube removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: change in clinical measures of movement speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects achieving HBA1c of 6% without diabetic medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of subjects achieving systolic BP <130mm hg without antihypertension medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of subjects achieving LDL level of <100mg/dl without lipid lowering medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total small vessel density of sublingual small vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Compliance with Annual Anal HPV DNA Screening
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Hemostasis within 15 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cartilage Oligomeric Matrix Protein (COMP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom From AV Access Circuit Localized or Systemic Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of life related to oral health
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Breastfeeding assessment score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attainment of therapeutic exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of Truvada concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Progression Free Survival at Six Months
Endpoint domain: Mortality/survival
Primary endpoint: Discomfort of lesions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total cholesterol, LDL-cholesterol, HDL-cholesterol, and Triglycerides levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Post Vaccination Geometric Mean Titers (GMTs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fractional Iron absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of TMS measurement of cortical excitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Alcohol Consumption
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in mRNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Number of Deaths Reported in Participants
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Who Experienced Relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Number of HCV Genotype (GT)1a-Infected Participants With Persistence of Treatment-Emergent Substitutions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: change in total vascular resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Percentage recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in Fasting Triglyceride Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of Patients With HPA Axis Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Freedom from plaque prolapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants accessing technical assistance resource webpage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: levels of neuropeptide Y
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emergence delirium
Endpoint domain: Adverse events/effects
Primary endpoint: Satisfaction scores by endoscopist
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to the first adequate device shock
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cf-DNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Posttransplant Virologic Response (pTVR) at Posttransplant Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Experiencing Any Adverse Event Leading to Permanent Discontinuation of Sofosbuvir Prior to Receiving Transplant
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Graft Loss Following Transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Expected Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Major adverse cardiac and cerebrovascular event (MACE)
Endpoint domain: Adverse events/effects
Primary endpoint: Reliability of the CVSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expiratory airflow obstruction (FEV1/FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Plasma Concentration at 24 Hours Post-dose (C24hr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma-concentration Curve at Zero to 24 Hours Post-dose (AUC[0-24hr])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Post-dose Plasma Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time Required for Plasma Concentration of MK-8189 to Decrease by Half (Apparent t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial Glucose Utilization Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Myocardial Glucose Utilization Rate Per Unit Insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Myocardial Fatty Acid Utilization Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Myocardial Fatty Acid Oxidation Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Myocardial Fatty Acid Esterification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin-stimulated glycogen synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: maximum plasma drug concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time at which maximum plasma concentration is observed (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the plasma concentration vs. time curve (AUC0-t and AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain Function measured by fMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Memory measured by Mnemonic Similarity Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to Anion Gap Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Youths With Antipsychotic Orders at 6 Months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Days' Supply of Antipsychotics Ordered for Youth
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Who Withdrew From Study Treatment Due to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: Variation of the percentage of healthy surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Body Temperature (BT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Respiratory Rate (RR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Heart Rate (HR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in patient-centredness level
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of patients who adequately mobilize stem cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Sensitivity and specificity of the Liat Strep A assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of fibrinolysis (mg/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of plasminogen (mg/ml) consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of inflammatory response (mg/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Absolute Psoriasis Area and Severity Index (PASI) at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Psoriasis Area and Severity Index at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants who Achieved Psoriasis Area and Severity Index 75, 90, and 100 Responses at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in tumor metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of participants who are continuously abstinent from cigarettes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Seroconverted Subjects for HI Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HIV viral reservoir
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Change From Baseline in Assessment of Negative Symptoms (SANS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in MATRICS Consensus Cognitive Battery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in Standard Deviation of Lateral Position (SDLP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PAF levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Charlson Comorbidity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average cross sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Level of Harmane in Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Urinary Oxalate Excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Biochemical prostate specific antigen (PSA) progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scale for the Assessment and Rating of Ataxia (SARA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Duration of the loss of anosmia and ageusia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Index of apneas and hypopneas (IAH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Montgomery-Åsberg Depression Rating Scale (MADRS) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Symptom Free Days
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Meal fat absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Meal fat storage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sertraline Plasma Concentrations/Area-Under-the-Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Average Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pneumothorax occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Global clinical improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants Who Drop-Out Before T-Cell Transfer
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Subjects who experience infusion-related adverse events following CMV-VST infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects who experience newly occurring acute GVHD grade ≥ 2 or experience aggravation of pre-existing acute GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Metabolic Complete Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospitalizations for major coronary events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Framingham 10-yr score for coronary heart disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of composite of acute rejection, graft loss or patient death
Endpoint domain: Mortality/survival
Primary endpoint: Change in hot flash rate occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of undiagnosed atrial fibrillation (AF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Engraftment - Chimerism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scapholunate diastasis (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scapholunate angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lunocapitate angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posterior radio scaphoid angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from maximum muscle torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction in the number of osteoclasts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: reduction of awareness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: MoCA Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Composite Cognitive Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Signal to Noise Ratio (SNR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T2*-Relaxation Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of Treatment Response to Decompression Surgery and Stem Cell Transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diurnal temperature variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Core body temperature and psychotic symptomatology ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epidermal Growth Factor Receptor (EGFR) expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Severe Impairment Battery (SIB) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: goal serum uric acid level of < 6 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mortality at the 45th day
Endpoint domain: Mortality/survival
Primary endpoint: Neonatal insulin-glucose index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma drug levels of Rifampicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma drug levels of Isoniazid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma drug levels of Pyrazinamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma drug levels of Ethambutol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long term safety of Adalimumab
Endpoint domain: Adverse events/effects
Primary endpoint: Evaluation of any new infection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Self-Centering Guide Catheters Successfully Used
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complete Response Rate to Chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean change from baseline in HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total HIV DNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD8 T-cell Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Replication Competent Reservoir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour sputum volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in child body mass index (BMI) z score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mutation rate of common seizure genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of seizure free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean salivary pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of dermic irritability and sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Development of food preferences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in brain reward response to food cues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numeric change of urgency episodes per 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Completed Each Arm on Assigned Study Drug Dose
Endpoint domain: Adverse events/effects
Primary endpoint: percentage of patients attaining ≥ 3 pre-defined treatment targets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Positive Reaction Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Afebrile within 5 days of the initial treatment regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nephrotoxicity and ototoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Current pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hemodynamic impacts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in endurance endpoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with pain or other discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with varicose veins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with active ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area-under-the-concentration curve (AUC) of rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SN-EASI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of participants experiencing adverse drug reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants experiencing serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants experiencing adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Success of endoscopic dilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tooth vitality response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean Daily Reflective Total Nasal Symptom (rTNSS) Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in rebleeds by ≥ 50% at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: Systemic adverse reactions
Endpoint domain: Adverse events/effects